Skip to content

Brivanib

DRUG15 trials

Sponsors

Bristol-Myers Squibb, M.D. Anderson Cancer Center, Hunan Cancer Hospital

Conditions

Advanced Non-small Cell Lung CancerCarcinoma, HepatocellularColorectal AdenocarcinomaColorectal CancerGastric/Esophageal AdenocarcinomaGastro-Intestinal CancerHepato Cellular Carcinoma (HCC)Hepatocellular Carcinoma

Phase 1

MAD in Cancer Patients: Safety of BMS-582664 in Patients With Advanced or Metastatic Solid Tumors
CompletedNCT00207103
Bristol-Myers SquibbNeoplasm Metastasis, Tumors
Start: 2004-09-30End: 2008-09-30Updated: 2008-11-04
A Study of BMS-582664 in Patients With Advanced or Metastatic Solid Tumors
CompletedNCT00390936
Bristol-Myers SquibbSolid Tumors
Start: 2007-10-31End: 2010-03-31Updated: 2011-01-25
A Phase I Study to Determine Absorption, Distribution, Metabolism, and Elimination of a Single Radiolabeled Dose of Brivanib (BMS-582664)
CompletedNCT00435669
Bristol-Myers SquibbTumors
Start: 2007-09-30End: 2008-06-30Updated: 2009-01-22
A Phase I Study to Determine the Effect of Food on Brivanib (BMS-582664)
CompletedNCT00437437
Bristol-Myers SquibbTumors
Start: 2000-05-31End: 2013-02-28Updated: 2013-06-21
A Study of Brivanib (BMS-582664) in Patients With Liver Cancer and Mild, Moderate or Severe Liver Dysfunction
CompletedNCT00437424
Bristol-Myers SquibbCarcinoma, Hepatocellular
Start: 2007-07-31End: 2010-06-30Updated: 2011-05-04
Phase I/II Combination With Irinotecan- Erbitux
CompletedNCT00594984
Bristol-Myers SquibbMetastatic Colorectal Cancer (MCRC)
Start: 2008-05-31End: 2012-12-31Updated: 2015-11-04
Combination of Brivanib With 5-Fluorouracil/Leucovorin (5FU/LV) and 5-Fluorouracil/Leucovorin/Irinotecan (FOLFIRI)
CompletedNCT01046864
Bristol-Myers SquibbGastro-Intestinal Cancer
Start: 2010-02-28End: 2014-06-30Updated: 2014-09-16
Determine the Pharmacokinetics and Safety of Brivanib in Chinese Subjects With Advanced Primary Liver Cancer (Hepatocellular Carcinoma: HCC)
CompletedNCT01540461
Bristol-Myers SquibbHepatocellular Carcinoma
Start: 2012-03-31End: 2013-11-30Updated: 2014-07-08
A Study of Niraparib in Combination With Brivanib in Recurrent Ovarian Cancer
NCT03895788
Hunan Cancer HospitalOvarian Cancer
Start: 2019-01-14End: 2020-03-31Target: 24Updated: 2019-03-29

Phase 2

Phase 3

Related Papers